Abstract:Background: Combinations of Chinese patent medicines (CPM) with antidepressants (including selective serotonin reuptake inhibitors (SSRI), selective serotonin-norepinephrine reuptake inhibitors (SNRI), tricyclic antidepressants (TCA), and noradrenergic and specific serotonergic antidepressants (NaSSA)) are frequently utilized for treating depression in adults. However, the efficacy and safety of these combination treatments remain to be established. Methods: Systematic search was conducted in seven electronic databases, regulatory websites and international registers of trials from 1994 to 2023 that included adult patients with depressive disorders who received CPM combined with antidepressants. The Multiple-Treatment Meta-Analysis (MTMA) was conducted using a random effects model with Stata/MP17 and R4.3.5 software. Primary outcomes were total efficacy rate, Hamilton Depression Scale (HAMD) score, and Treatment Emergency Symptom Scale (TESS) score. Secondary outcomes included brain-derived neurotrophic factor (BDNF) levels. Results: A total of 146 randomized controlled trials (13,754 participants: 6929 in intervention and 6825 in control groups) were included. For total effective rate, Multiple-Treatment Meta-Analysis results showed that the overall effect of combined intervention was better compared with antidepressants alone, where Jieyuanshenkeli (JYASKL) presented the optimal option for improving total efficacy (OR = 5.39, 95% CI [2.60, 11.18], SUCRA = 84.50%). In reduding the HAMD, Shuganjieyujiaonang (SGJYJN) was most likely to reduce the HAMD score (SMD = -2.20, 95% CI [-3.06, -1.33], SUCRA = 86.10%), Jieyuanshenkeli (JYASKL),Tianewangbuxindan (TWBXD), Shuyukeli (SYKL), Anshenbuxinwan (ASBXW) combination intervention did not appear to be statistically superior to antidepressants alone. In theTreatment Emergency Symptom Scale (TESS), Wulinjiaonang induced the most significant reduction in TESS score (SMD = -1.98, 95% CI [-3.59, -0.36], SUCRA = 90.40%). Tianmengjiaonang (TMJN) + Antidepressants(AD) (SUCRA = 88.30%) displayed the highest scores in increasing the levels of BDNF, although not statistically significant compared to Antidepressants(AD) alone (SMD = 1.23, 95% CI [0.90, 1.55]). Conclusion: Combinations of CPM and antidepressants showed superior efficacy over antidepressants alone. The optimal combinations were determined as Shuganjieyu Jiaonang (SGJYJN)/SSRIs and Jieyuanshenkeli (JYASKL)/SSRIs. In terms of safety, results showed that combination therapy did not show better TESS efficacy than antidepressants alone.Although some of the combination interventions were not superior than antidepressants alone in reducing HAMD scores,our findings provide a potentially significant alternative option for clinical complementary therapy. However, these results require further validation through larger sample sizes, multicenter randomized controlled trials, and real-world data.

Clinically study on 65 cases with depression treatment by tra ditional Chinese Medicine

A controlled study in the treatment of depression with escitalopram and paroxetine

Effectiveness and safety of Chaihu-Shugan-San for treating depression based on clinical cases: An updated systematic review and meta-analysis

Randomized, Double Blind, Placebo-Controlled Trial of Shuganjieyu Capsule in the Treatment of Mild or Moderate Depression

Meta-analysis of Acupuncture Combined with Paroxetine in the Treatment of Depression

Randomized, Double Blind, Double - Dummy, Multicenter, Parallel Controlled Clinical Trial of Kaiyuanshen in the Treatment of Depressive Disorder

To Observe the Therapeutic Effect of Escitalopram and Paroxetine on the Senile Depression

Efficacy and safety of Chinese patent medicines combined with antidepressants for treatment of depression in adults: A multiple-treatment meta-analysis

Duloxetine Versus Paroxetine in the Treatment of Major Depressive Disorder: a Randomized Double-Blind Multicentre Controlled Study

A comparative study of domestic and imported proucts of paroxetine on efficacy and safety in patients with major depression

The effect evaluation of electroacupuncture improving therapeutic effects and decreasing the side-effects of Paroxetine for mild or moderate depression patients

Treatment of Major Depressive Disorders with Generic Duloxetine and Paroxetine: a Multi-Centered, Double-Blind, Double-Dummy, Randomized Controlled Clinical Trial.

Effect of Electroacupuncture on Therapeutic Effects and Onset Time of Paroxetine for Mild or Moderate Depression Patients

CLINICAL CONTROL STUDY OF DEANXIT COMBINED WITH PAROXETINE TREATMENT IN NEWLY DIAGNOSED DEPRESSION

Efficacy and safety of double doses of SHUGANJIEYU capsules in treating moderate depressive disor-der:a multicenter, random, double-blind, and parallel-controlled trial

Clinical Research on Treatment of Depression with Electric Acupuncture and SSRI

Chinese herbal medicines for the treatment of depression: a systematic review and network meta-analysis

A Randomized, Double-Blind, Positive-Controlled, Multicenter Clinical Trial on the Efficacy and Safety of ShuganJieyu Capsule and St. John's Wort for Major Depressive Disorder with Somatic Complaints

Randomized,double-blind controlled study of Duloxetine enteric tables in treatment of depression

Efficacy and Safety of Generic Escitalopram Versus Lexapro in the Treatment of Major Depression: a Multicenter Double-Blinded Randomized Controlled Trial.

Oberserved the Effects Treatmed in Depression And/or Anxiety Patients Expressed in Physical Sympotoms with Deanxit or Paroxetine